BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: FDA writes MicroMed cryptic warning for event reporting

Jan. 7, 2010
By Mark McCarty

Long-term care issues revolve around ageless issue of cost

Jan. 6, 2010
By Mark McCarty

Washington roundup: ACC sues over SGR fee cuts to Medicare Part B payments

Dec. 31, 2009
By Mark McCarty

Washington roundup: JAMA: devices are subject to less scrutiny than drugs

Dec. 30, 2009
By Mark McCarty
The process of clearance and approval of medical devices has been all over the media radar screen, and the Journal of the American Medical Association (JAMA) has chimed in with an article alleging that device applications have been subjected to less scrutiny than drug applications. (Medical Device Daily)
Read More

Washington roundup: NICE indicates unwillingness to cover dronedarone for afib

Dec. 29, 2009
By Mark McCarty

Washington roundup: Senate's health reform bill faces merger with House bill

Dec. 28, 2009
By Mark McCarty
The U.S. Senate has pushed through a healthcare reform bill – a mammoth 2,500-page chunk of legislation with bargains grand and petite for a number of stakeholders – by a party-line vote of 60-39. Despite the seeming momentousness of the occasion, one last hurdle remains: managing the merger of the Senate's legislative tome with the relatively house bill, which comes in at roughly 1,100 pages. (Medical Device Daily)
Read More

Washington roundup: FDA slams fertility clinic for site monitoring lapses

Dec. 24, 2009
By Mark McCarty

Washington roundup: Envoy wins panel nod for its Esteem hearing implant PMA

Dec. 22, 2009
By Mark McCarty
GAITHERSBURG, Maryland — The ear, nose and throat devices advisory committee met last week to take up the matter of the Esteem implant for hearing loss, made by Envoy Medical (St. Paul, Minnesota) and as is often the case of late with medical device advisory committees, the agency allowed the panel to take up a matter that is outside the panel's purview. (Medical Device Daily)
Read More

Washington roundup: AdvaMed opens new division for diagnostics member firms

Dec. 21, 2009
By Mark McCarty

Washington roundup: Small business group aims to tackle patent reform issues

Dec. 18, 2009
By Mark McCarty
Previous 1 2 … 491 492 493 494 495 496 497 498 499 … 576 577 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing